Maryann Zhao

Dec 10, 2024 | nature.com | Maryann Zhao |Jonathan D Schoenfeld

AbstractImmune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various solid tumours, including in patients with head and neck squamous cell carcinoma (HNSCC), with promising results. Key findings thus far include that this approach is well-tolerated with favourable clinical outcomes including promising pathological response rates in initial studies. Pathological responses are likely to be increased by combining other agents with anti-PD-(L)1 antibodies.

Jul 15, 2024 | nature.com | Alexandra Schnell |Maryann Zhao |Elena Christian |Sarah Zaghouani |Vasundhara Singh |Anvita Singaraju | +6 more

AbstractInterleukin-17 (IL-17)-producing helper T (TH17) cells are heterogenous and consist of nonpathogenic TH17 (npTH17) cells that contribute to tissue homeostasis and pathogenic TH17 (pTH17) cells that mediate tissue inflammation. Here, we characterize regulatory pathways underlying TH17 heterogeneity and discover substantial differences in the chromatin landscape of npTH17 and pTH17 cells both in vitro and in vivo.